Minaprine

Minaprine
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	N06AX07 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Elimination half-life	2-2.5 hours
Identifiers
	IUPAC name 4-methyl-N-(2-morpholin-4-ylethyl)-6-phenylpyridazin-3-amine;
CAS Number	25905-77-5 ;
PubChem CID	4199;
ChemSpider	4054 ;
UNII	00U7GX0NLM;
KEGG	D05039 ;
ChEMBL	ChEMBL278819 ;
CompTox Dashboard (EPA)	DTXSID5048477 ;
ECHA InfoCard	100.043.012
Chemical and physical data
Formula	C17H22N4O
Molar mass	298.383 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3;
	(what is this?) (verify)

Minaprine (Brantur, Cantor) is an antidepressant used in France for the treatment of depression. It acts as a reversible inhibitor of MAO-A (RIMA).^[1] It has also been found to inhibit acetylcholinesterase.^[2]

Chemistry

References

^ Kan JP, Mouget-Goniot C, Worms P, Biziere K (1986). "Effect of the antidepressant minaprine on both forms of monoamine oxidase in the rat". Biochemical Pharmacology. 35 (6): 973–978. PMID 3954800.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Contreras JM, Rival YM, Chayer S, Bourguignon JJ, Wermuth CG (1999). "Aminopyridazines as acetylcholinesterase inhibitors". Journal of Medicinal Chemistry. 42 (4): 730–741. PMID 10052979.{{cite journal}}: CS1 maint: multiple names: authors list (link)

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[1] Kan JP, Mouget-Goniot C, Worms P, Biziere K (1986). "Effect of the antidepressant minaprine on both forms of monoamine oxidase in the rat". Biochemical Pharmacology. 35 (6): 973–978. PMID 3954800.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[2] Contreras JM, Rival YM, Chayer S, Bourguignon JJ, Wermuth CG (1999). "Aminopyridazines as acetylcholinesterase inhibitors". Journal of Medicinal Chemistry. 42 (4): 730–741. PMID 10052979.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[1]

[2]

v t e Anxiolytics (N05B)
5-HT_1ARTooltip 5-HT1A receptor agonists	Buspirone Gepirone Tandospirone
GABA_ARTooltip GABAA receptor PAMsTooltip positive allosteric modulators	Benzodiazepines: Adinazolam Alprazolam Bromazepam Camazepam Chlordiazepoxide Clobazam Clonazepam Clorazepate Clotiazepam Cloxazolam Diazepam^# Ethyl loflazepate Etizolam Fludiazepam Halazepam Ketazolam Lorazepam^# Medazepam Nordazepam Oxazepam Pinazepam Prazepam; Others: Alpidem^‡ Barbiturates (e.g., phenobarbital) Carbamates (e.g., meprobamate) Carisoprodol Chlormezanone^‡ Ethanol (alcohol) Etifoxine
Hypnotics	Zopiclone
Gabapentinoids (α₂δ VDCC blockers)	Gabapentin Gabapentin enacarbil Phenibut Pregabalin
Antidepressants	SSRIsTooltip Selective serotonin reuptake inhibitors (e.g., escitalopram) SNRIsTooltip Serotonin-norepinephrine reuptake inhibitors (e.g., duloxetine) SARIsTooltip Serotonin antagonist and reuptake inhibitors (e.g., trazodone) TCAsTooltip Tricyclic antidepressants (e.g., clomipramine^#) TeCAsTooltip Tetracyclic antidepressants (e.g., mirtazapine) MAOIsTooltip Monoamine oxidase inhibitors (e.g., phenelzine); Others: Agomelatine Bupropion Tianeptine Vilazodone Vortioxetine
Antipsychotics	Quetiapine Flupentixol
Sympatholytics (Antiadrenergics)	Alpha-1 blockers (e.g., prazosin) Alpha-2 agonists (e.g., clonidine, dexmedetomidine, guanfacine) Beta blockers (e.g., propranolol)
Others	Benzoctamine Cycloserine Fabomotizole Hydroxyzine Lorpiprazole Mebicar Mepiprazole Nicotine Opipramol Oxaflozane^‡ Phenaglycodol Phenibut Picamilon Selank Tiagabine Tofisopam Validolum
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

Chemistry

See also

References